Bausch & Lomb Introduces the Crystalens Aspheric Optic (AO) Lens

Article

Crystalens AO is the first aberration-free accommodating IOL

ALISO VIEJO, CALIF. -- Bausch & Lomb today announced that it is launching the Crystalens AO, the first aberration-free accommodating intraocular lens (IOL) with aspheric optics to cataract surgeons worldwide. The announcement follows the recent FDA approval of this newest Bausch & Lomb surgical product. The Crystalens AO, combined with the successful Crystalens HD and the Crystalens Five-0, will further establish Crystalens as the market leader in the premium IOL market.

The Crystalens AO has prolate aspheric surfaces and is designed to be free of spherical aberration. It is designed to improve retinal image quality without compromising depth of field and therefore provides greater quality of distance and intermediate vision.

“We are confident the Crystalens AO is an important addition to the Crystalens portfolio and along with Crystalens HD and Crystalens Five-0 will further establish Crystalens as the gold standard for quality of vision in the premium channel. Some surgeons might assume because the Crystalens has aspheric optics, depth of field will be reduced. However, our comprehensive testing demonstrates the opposite to be true. Not all aspheric lenses are created the same, and other aspheric IOLs have negative spherical aberration, which could reduce depth of field. The Crystalens AO has zero spherical aberration, and the combination of the Crystalens platform and AO optics work together to enhance depth of field,” said Andy Corley, global president, Surgical, Bausch & Lomb.

Crystalens is the only FDA-approved accommodating intraocular lens. Unlike a standard cataract replacement lens, Crystalens is designed to not only eliminate a patient’s cataract but to provide a full range of vision so that the patient can see near, far and everywhere in between. Many Crystalens patients hardly, if ever, need their glasses after surgery. The Crystalens AO takes the best of Bausch & Lomb’s heritage of aspheric optics and combines it with the company’s Crystalens platform.

“The Crystalens AO provides patients an opportunity to enjoy improved post-operative vision through an increase in contrast sensitivity due to the absence of spherical and higher order aberrations. This, along with the general consensus that the best technology for treatment of presbyopic patients is an accommodating lens, will encourage many surgeons to adopt this new product,” said Jay Pepose, MD, PhD, of the Pepose Vision Institute St. Louis, Mo.

There are three million cataract surgeries every year in the U.S. A cataract is a clouding of the normal clear lens in the eye. When a cataract forms, the natural lens in the eye is replaced by an intraocular lens. The Crystalens is an intraocular lens that is designed not only to fix a patient’s cataract, but to help improve the patient’s full range of vision.

“We know that many surgeons prefer aspheric lenses because they believe that they correct for spherical aberrations and provide better quality of vision. We believe that the Crystalens AO will be viewed very favorably to competitive lenses and will be attractive to a wider range of surgeons and patients,” said Amy Jacobs, director of Global Marketing for the Crystalens.

The Crystalens AO is comprised of proprietary biosil silicone and has a thin and uninterrupted barrier edge. It will be inserted using the CI-28 injector in a controlled manner through an un-enlarged phaco incision which is a routine requirement in today’s cataract surgical procedure.

The Crystalens AO worldwide launch is expected to accelerate through the first quarter of 2010.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.